Article Title



Margaret I. Damare, Lauren C. Bates, Erik D. Hanson, FACSM, Lee Stoner, FACSM. University of North Carolina at Chapel Hill, Chapel Hill, NC.

BACKGROUND: Among endometrial cancer (EC) survivors, the major cause of death is cardiovascular disease (CVD). Factors contributing to the heightened CVD risk include the cancer treatment and lifestyle behaviors. Conversely, CVD risk can be decreased through engagement in healthy lifestyle behaviors. Sedentary behavior (SB, ≤1.5 METs in seated/reclined position) reduction may be a feasible target for decreasing CVD risk in EC survivors. EC survivors have been reported to engage in high amounts of SB, a behavior which strongly associated with CVD mortality and morbidity. However, it is unknown what type and dose of SB interruption will be most feasible for EC survivors. Therefore, this study will investigate simple strategies to substitute SB (standing or walking) in EC survivors to investigate which type and dose reduces CVD burden associated with sitting. METHODS: The proposed randomized, controlled cross-over trial will recruit 20 EC survivors aged ≥50 years. Subjects will complete three SB conditions each lasting 2.5 hours. Two substitution conditions will interrupt sitting for 5 mins/hour via standing or walking because these are simple, cost-effective, potentially feasible strategies in real-world settings. The control condition will be uninterrupted SB. The primary outcome will be aortic arterial stiffness, measured using carotid-femoral pulse wave velocity (cfPWV) The cfPWV is the gold-standard noninvasive measure of CVD risk and has been reported to acute increase with exposure to prolonged sitting. Changes in cfPWV across the three conditions will be compared using a mixed model, with subject specified as random and time and condition as fixed effects. ANTICIPATED RESULTS: We anticipate that the findings of this study will facilitate the development of a feasible (low-cost and simple) and effective SB substitution recommendation for EC survivors. The findings will guide the development of an interventional study to test our recommended SB substitution strategy in EC survivors in the real-world.

This document is currently not available here.